Entries by Thomas Gabrielczyk

Poolbeg takes centre stage in CRS research

Cancer immunotherapies can save lives, yet their side effect — cytokine release syndrome (CRS) — remains a barrier for wider use, even though IL 6 receptor antagonists can treat it. Now the UK company Poolbeg Pharma plc, together with Johnson & Johnson, investigates how CRS might be prevented. The programme is backed by a £3.4m grant from the MRC.

EU trilogue sets clear path for new genomic techniques

After four EU Council presidencies, EU member states and the European Parliament yesterday struck a provisional deal on new genomic techniques under the current Danish presidency, setting clear rules to boost agrifood innovation, plant resilience, transparency and sustainability.